-+ 0.00%
-+ 0.00%
-+ 0.00%

Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction

Barchart·07/27/2026 09:49:00
Listen to the news

Kennewick, WA, July 27, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy, is pleased to share this update on the meaningful advancements the company has made across our core initiatives. Our team remains focused on advancing Precision Radionuclide Therapy (PRnT), our proprietary yttrium-90-based injectable hydrogel technology, to deliver accessible treatments for cancerous tumors in both humans (RadioGel®) and animals (IsoPet®).

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.